UPDRS Part III scores were significantly lower
with zonisamide than with placebo (weighted mean difference [WMD], — 2.56; 95 % confidence interval [CI]; — 4.20 to — 0.92; p = 0.002).
Not exact matches
Of those treated
with a single medication, nearly all were treated
with one of five medicines: Levetiracetam, oxcarbazepine, phenobarbital, topiramate and
zonisamide.
Further,
zonisamide significantly decreased the wearing - off time compared
with placebo (standardized mean difference, — 0.24; 95 % CI, — 0.39 to — 0.09; p = 0.001).
Risk may be higher
with long - term treatment (12) and concurrent use of carbonic anhydrase inhibitors such as topiramate or
zonisamide (24).
Zonisamide can be prescribed as a lone therapy, but it is most commonly given as an add - on medication
with either phenobarbital or potassium bromide.
Zonisamide can be used by itself as well as combined
with other anticonvulsant medications.
Zonisamide can be used alone or in combination
with Phenobarbital and / or potassium bromide for treating seizures.
As
with most anticonvulsant drugs, however,
Zonisamide can cause drowsiness, incoordination (loss of muscle control), and a depressed appetite in dogs.
While
Zonisamide appears to be relatively safe for dogs, is effective in controlling seizures, and is well - tolerated, many veterinarians are still concerned that we may not know the entire range of side effects possible
with the drug because its use has been somewhat limited so far.